Navigation Links
CVS Caremark Corporation Announces Receipt of Requisite Consents, Termination of Replacement Capital Covenant and Expiration of Consent Solicitation Relating to its 6.125% Senior Notes due August 15, 2016 (CUSIP NO. 126650BE9)
Date:8/22/2011

WOONSOCKET, R.I., Aug. 22, 2011 /PRNewswire/ -- CVS Caremark Corporation (NYSE: CVS) announced today the results of its previously announced solicitation of consents (the "Consent Solicitation") from the registered holders as of 5:00 p.m., New York City time on August 8, 2011 (the "Record Date") of its 6.125% Senior Notes due August 15, 2016 (the "Notes") to terminate the replacement capital covenant, which was entered into on May 25, 2007, for the benefit of the holders of the Notes in connection with the issuance of its 6.302% Enhanced Capital Advantaged Preferred Securities due 2062 (the "ECAPS").  Under the replacement capital covenant, CVS Caremark was prohibited from repurchasing, redeeming or repaying its ECAPS on or before June 1, 2047 unless a specified portion of the funds used to repay, redeem or repurchase the ECAPS were obtained by CVS Caremark through the sale of common stock or certain other equity or equity-like securities.

(Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO)

The Consent Solicitation expired at 5:00 p.m., New York City time, on August 22, 2011.  The termination of the replacement capital covenant required the consent of the holders of a majority in aggregate principal amount of the outstanding Notes (the "Requisite Consents").  Based on the final tabulation provided by the Information and Tabulation Agent for the Consent Solicitation, D.F. King & Co., Inc., the holders of approximately 619,838,000 Notes, or approximately 88.55% of the aggregate principal amount outstanding, delivered duly executed consents prior to the expiration of the Consent Solicitation.

CVS Caremark has executed a termination of the replacement capital covenant and will make a cash payment to each holder of the Notes of $15.00 per $1,000 in principal amount of the Notes as to which a duly executed consent was delivered and not revoked on or prior to the expiration of the Consent Solicitation.  

For a complete statement of the terms and conditions of the Consent Solicitation, holders of the Notes should refer to the Consent Solicitation Statement and the consent form dated August 9, 2011.  Copies of the Consent Solicitation Statement and the consent form may be obtained from D.F. King & Co., Inc. at (800) 949-2583 (toll-free).

Barclays Capital Inc. and RBS Securities Inc. acted as the Solicitation Agents for the Consent Solicitation. 

About the Company:

CVS Caremark is the largest pharmacy health care provider in the United States with integrated offerings across the entire spectrum of pharmacy care. We are uniquely positioned to engage plan members in behaviors that improve their health and to lower overall health care costs for health plans, plan sponsors and their members. CVS Caremark is a market leader in mail order pharmacy, retail pharmacy, specialty pharmacy, and retail clinics, and is a leading provider of Medicare Part D Prescription Drug Plans. As one of the country's largest pharmacy benefits managers (PBMs), we provide access to a network of approximately 65,000 pharmacies, including approximately 7,300 CVS/pharmacy® stores that provide unparalleled service and capabilities. Our clinical offerings include our signature Pharmacy Advisor™ program as well as innovative generic step therapy and genetic benefit management programs that promote more cost effective and healthier behaviors and improve health care outcomes. General information about CVS Caremark is available through the Company's website at http://info.cvscaremark.com.

Forward-looking Statements:

This press release contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. For these statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2010 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q.  


'/>"/>
SOURCE CVS Caremark Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CVS Caremark Appoints Mark S. Cosby as President of CVS/pharmacy
2. CVS Caremark, Harvard and Brigham and Womens Researchers Say Medicare Donut Hole Can Lead to a Decrease in Medication Adherence
3. CVS Caremark Corporation Announces Consent Solicitation Relating to Its 6.125% Senior Notes Due August 15, 2016 (CUSIP NO. 126650 BE 9)
4. CVS Caremark Reports Second Quarter Results
5. CVS Caremark Showcases Workplace and Marketplace Diversity at 2011 National Urban League Conference
6. CVS Caremark Corporation to Hold Second Quarter 2011 Conference Call
7. Access Pharmaceuticals MuGard Added to CVS Caremarks Pharmacy Benefit Network
8. CVS Caremark, Harvard and Brigham and Womens Research Shows Generic Medications are Changing the Economics of Treating Chronically Ill Patients
9. CVS Caremark Corporation Announces Quarterly Dividend
10. CVS Caremark to Present at the Jefferies 2011 Global Consumer Conference
11. CVS Caremark and Area Colleagues Provide $40,000 of Support to Tornado Relief Efforts in Joplin, MO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... May 31, 2016 RnRMarketResearch.com adds ... with comparative analysis of Asthma therapy at various stages, ... route of administration (RoA) and molecule type, along with ... also reviews key players involved in the therapeutic development ... projects. Complete report on H1 2016 pipeline ...
(Date:5/30/2016)... On 28 May, 194 Member States made a historic ... th World Health Assembly, governments unanimously voted to adopt ... global commitment in viral hepatitis to date. The ... by 2030 and includes a set of prevention and treatment ... and increase treatment to 80%, saving 7.1 million lives globally ...
(Date:5/27/2016)... Israel , May 27, 2016 ... of the Dario™ Diabetes Management Tool, today announced that the ... at the Marcum MicroCap Conference being held June 1-2 in ... Micro Invitational, being held June 7-9 in Los ... Ben-David will discuss recent corporate and operational milestones, including the ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... Interest is on the rise for ... as an orthogonal tool for RNAi hit validation. A key reason may be that ... rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. , Arrayed ...
(Date:5/31/2016)... ... 31, 2016 , ... In a recent interview on The Greenburgh Report radio ... NY-based WVOX (1460 AM), leading medical insurance advocate Adria Goldman Gross discussed ... medical money maelstrom.” , During the interview with Mr. Feiner that aired on ...
(Date:5/31/2016)... ... May 31, 2016 , ... Advertising ... firm and statement solutions provider, for the tenth consecutive year as a Top ... of Advertising Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing Agency” ...
(Date:5/31/2016)... Port Washington, NY (PRWEB) , ... May 31, 2016 , ... ... and other essential nutrients to on the go individuals and dedicated athletes, continues to ... functions. , Loaded with whey, pea and milk protein, branched-chain amino acids (BCAA), ...
(Date:5/30/2016)... ... May 30, 2016 , ... ... announced today the publication of an original infographic, " Health Benefits Reimbursement Compliance ... professionals understand how Zane Benefits complies with various federal regulations and reforms. , ...
Breaking Medicine News(10 mins):